TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04611854

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guidance
Description: Guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ICBT for alcohol misuse
Description: The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 8 lessons distributed across 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT for alcohol misuse
Description: The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 8 lessons distributed across 8 weeks.
Study: NCT03864445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7791
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebp
Description: oral administration
Study: NCT02914054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose Dexamethasone pulses
Description: In HD-DXM arm, DXM was administered intravenously at 40 mg in 500cc normal saline (0.9% saline) during 1 hour for consecutive 4 days and then stopped. This cycle was repeated in 14 days interval to receive 3 cycles of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Patients in PDN arm received PDN orally at 1.0 mg/kg body weight daily for 4 consecutive weeks. After achieving responses the medication tapered gradually to less than 15mg daily or terminated over 4-6 weeks aimed at maintaining platelet count over 30 ×109/L.
Study: NCT00470236

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard WB fractionation
Description: A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Shorter WB fractionation
Description: A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard WB fractionation+Boost
Description: Whole Breast: A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).~Tumour bed: A total dose of 10 Gy in 5 fractions in 2-Gy daily fractions, 5 fractions per week.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Shorter WB fractionation + Boost
Description: Whole breast: A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).~Tumour bed: A total dose of 10 Gy in 4 fractions in 2.5-Gy daily fractions, 4 fractions per week.
Study: NCT00619528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of Donor Hematopoietic Stem Cells and Campath-1H
Description: Intervention: a four-dose (peri-operative and 3, 6, and 9-month boost) DHSC infusion protocol using two-dose Campath-1H induction combined with transient (conditioning) Tacrolimus/Sirolimus and MMF therapy will result in a high degree of macro-chimerism (\>10%), and a robust prolonged donor-specific (post-thymic) immunoregulatory condition that will allow renal transplant survival in the absence of permanent immunosuppression.
Study: NCT03627897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: The erector spinae plane blocks proceed with 0,5 ml/kg of 0,25% bupivacain (Group B).

Intervention type: DRUG
Group type: OTHER
Intervention: saline
Description: No drugs or interventions were administered to the control group.
Study: NCT02648516

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conventional plus AAIT
Description: Participants will receive ART and taken i.v., at a dose of 2-3\*10E8 MNCs/kg body at baseline, week 1 and 2.
Study: NCT02104154

Intervention type: DEVICE
Intervention: Samsung LABGEO PT10 Hepatic Panel
Study: NCT01921855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY Factor VII (BAY86-6150)
Description: BAY Factor VII (BAY86-6150), 6.5 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY Factor VII (BAY86-6150)
Description: BAY Factor VII (BAY86-6150), 20 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY Factor VII (BAY86-6150)
Description: BAY Factor VII (BAY86-6150), 50 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY Factor VII (BAY86-6150)
Description: BAY Factor VII (BAY86-6150), 90 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
Study: NCT00224094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin® (oral) vs. Alora® (transdermal)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin® (oral) vs. Alora® (transdermal)
Study: NCT02679599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B-MOBILE-CARDIAC smartphone application

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cardiac rehabilitation as usual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation as usual
Study: NCT01115842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 4000IU per day for 5 days
Study: NCT03526887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg, Q3W
Study: NCT02933736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Study: NCT04128345

Intervention type: DEVICE
Intervention: Use of navigation system
Description: Feasibility assessment of using an integrated navigation system incorporating advanced diffusion MRI, volumentric tumour representation and intraoperative ultrasound
Study: NCT01824680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: There is two sequences, one before and one after the physical activity program. Each sequence contains one rest session and one exercise session
Study: NCT04677699

Intervention type: DIAGNOSTIC_TEST
Intervention: Combined Risk Score
Description: Several factors will be analyzed to assign each subject combined risk score. This will assess the subject's risk of developing Type 1 Diabetes and/or Celiac Disease.

Intervention type: DIAGNOSTIC_TEST
Intervention: Combined Risk Score
Description: Several factors will be analyzed to assign each subject combined risk score. This will assess the subject's risk of developing Type 1 Diabetes and/or Celiac Disease.
Study: NCT01460186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample for genetic analysis (Identification of germ line genetic factors that influence the risk of metastatic breast cancer)
Description: Blood samples will be collected in one 6 ml EDTA and one 6 ml ACD tube after informed consent and inclusion in the study.
Study: NCT01448239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab SAR236553 (REGN727)
Description: Pharmaceutical form:Solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab SAR236553 (REGN727)
Description: Pharmaceutical form:Solution Route of administration: Subcutaneous
Study: NCT02634203

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon Pulmonary Angioplasty (BPA)
Description: Balloon pulmonary angioplasty (BPA) will be done via femoral vein. 2 sessions will be performed during the same hospitalization following by additional sessions at an interval of 2-3 weeks until a mean PAP\< 30 mmHg is achieved A pulmonary angiography and a right heart catheterization will be performed at each BPA session

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riociguat
Description: The starting dose will be 1 mg three times daily as recommended. The dose will be titrated every 2 weeks according to the peripheral systolic pressure. Dose should be increased by 0.5 mg three times daily every two weeks to a maximum of 2.5 mg three times daily, if systolic blood pressure is ≥95 mmHg and the patient has no signs or symptoms of hypotension.
Study: NCT01230554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daily disposable cosmetic tint lens
Description: Bausch \& Lomb daily disposable cosmetic tint contact lens worn on a daily disposable basis for 1 week.
Study: NCT04554238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo spring
Description: Armeo spring is an exoskeleton that allows intensive therapy aimed at upper extremity tasks, which can be regulated according to the anthropometric measurements of the child and the objective of the session. The software contains an extensive library of game-like exercises that are run in a motivating and informative virtual reality training environment, clearly showing the functional task to be performed through immediate feedback in a 3D work space.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: This treatment includes passive stretching exercises, weight bearing, stimulation of protective reactions, muscle strengthening exercises and different types of motivating bimanual games, favoring reaching, grasping, exploration and manipulation.
Study: NCT01033435

Intervention type: OTHER
Intervention: No intervention
Study: NCT01581944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 Doses Goserelin
Description: 3.6mg administered monthly for 2 months prior to myomectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 Doses Goserelin
Description: 3.6mg administered monthly for 3 months prior to myomectomy
Study: NCT00809523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Ion Generator
Description: Equivalent exposure to inactivated Negative Ion Generator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light-emitting Photodiode light treatment device
Description: Light-emitting Photodiode light treatment device, used for 30 min before 8 am
Study: NCT04039854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane, Sevoflurane or Desflurane
Description: The volatile anaesthetic agent will be administered via inhalation, i.e. ventilation through alveolar membrane in lungs) during the maintenance of anaesthesia. During CPB the volatile anaesthetic agent will be administered through the oxygenator oxygen inflow of the CPB machine.~The maintenance dose of the volatile anaesthetic agent will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia and blood pressure.~The administration of the volatile anaesthetic agent will be started after induction of anaesthesia and it will be ended at the end of surgery, before the patient is transferred to the CCU.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patients will receive propofol only during the surgical procedure. The maintenance dose of the propofol infusion will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia (titrated to a depth of anaesthesia with BIS 30-60) and mean arterial pressure (MAP) of 50-80mmHg by the treating anaesthetist.
Study: NCT00369785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil hydrochloride
Description: Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day
Study: NCT03202784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353
Description: BCX7353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353
Description: BCX7353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353
Description: BCX7353
Study: NCT03628937

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Decaffeinated Green Tea Polyphenol
Description: Intervention group will be given decaffeinated green tea polyphenol capsules (400 mg, EGCG accounted for 50%). Participants need take it once a day after breakfast for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: The starch capsule was used as a placebo control, which has the same dosage, appearance and smell compared to decaffeinated green tea polyphenol capsule. The use frequency and duration are consistent with intervention group.
Study: NCT02414568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine 120 mg/m2 (IV) Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 40 mg/m² PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastine 6 mg/m² IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 40 mg/m² IV
Study: NCT04408014

Intervention type: DIAGNOSTIC_TEST
Intervention: Serological test
Description: IgM and IgG for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Serological test
Description: IgM and IgG for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Serological test
Description: IgM and IgG for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Serological test
Description: IgM and IgG for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Serological test
Description: IgM and IgG for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Serological test
Description: IgM and IgG for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Serological test
Description: IgM and IgG for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Serological test
Description: IgM and IgG for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal Swab
Description: PCR for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal Swab
Description: PCR for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal Swab
Description: PCR for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal Swab
Description: PCR for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal Swab
Description: PCR for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal Swab
Description: PCR for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal Swab
Description: PCR for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Oropharyngeal Swab
Description: PCR for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Oropharyngeal Swab
Description: PCR for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Oropharyngeal Swab
Description: PCR for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Oropharyngeal Swab
Description: PCR for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Oropharyngeal Swab
Description: PCR for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Oropharyngeal Swab
Description: PCR for SARS-CoV-2

Intervention type: DIAGNOSTIC_TEST
Intervention: Oropharyngeal Swab
Description: PCR for SARS-CoV-2
Study: NCT04652713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein-rich breakfast
Description: High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) yoghurt with 40 g oats for breakfast.~1 glas of water (150 ml)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich breakfast
Description: Low protein breakfast containing approx. 2 g protein per 100 g. Participants will be asked to consume \~60 g bread, 20 g jam and 250 ml juice for breakfast.~1 glas of water (150 ml)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No breakfast
Description: 1 glas of water (150 ml)
Study: NCT03244410

Intervention type: DIAGNOSTIC_TEST
Intervention: complete blood picture
Description: complete blood picture
Study: NCT02900183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-AAT Injection
Description: RNA interference (RNAi)-based, liver-targeted therapeutic
Study: NCT05362383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical nerve stimulation (TENS):Enraf Nonius® S82 model
Description: Will be used TENS device with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 milliampere. TENS electrodes (diameter 35-52 mm) will be placed bilaterally on mandibular elevator muscles, on the superficial masseter muscle above the gonial angle, and bilaterally on the anterior temporal muscle. The device will be applied in an identical manner to all patients in both groups and kept in position for the same time period (30 min) and for the control group the the device will be not switched on
Study: NCT04611620

Intervention type: BEHAVIORAL
Intervention: Cognitive Dysfunction
Description: To fully characterize factors associated with cognitive dysfunction in BCS and CRC survivors that have cognitive concerns and (2) to fully characterize factors associated with psychoneurological symptom cluster in BCS and CRC survivors.
Study: NCT03841695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RMTC finger-hand robot (Mirror Hand)
Description: The robotic hand will apply on the patient's affected hand and the sensor glove will apply on the patient's un-affected hand, the patient can manipulate their affected hand by their un-affected hand and do the task oriented bimanual training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional OT
Description: The focus of occupational therapy is to help individuals achieve health, well-being, and participation in life through engagement in activities (American Occupational Therapy Association \[AOTA\], 2014). For stroke rehabilitation, occupational therapy includes retraining in self-care skills, addressing ongoing deficits such as weakness, sensory loss, and cognitive impairments that limit engagement in activities of daily living, and training in community reintegration and modifying tasks or environments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional OT
Description: The focus of occupational therapy is to help individuals achieve health, well-being, and participation in life through engagement in activities (American Occupational Therapy Association \[AOTA\], 2014). For stroke rehabilitation, occupational therapy includes retraining in self-care skills, addressing ongoing deficits such as weakness, sensory loss, and cognitive impairments that limit engagement in activities of daily living, and training in community reintegration and modifying tasks or environments.
Study: NCT00870766

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal contrast-enhanced CT scanning
Description: Contrast-enhanced (iohexol 350 mgI/ml, 100 ml IV) CT scanning
Study: NCT03641495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PE+ET
Description: To explain the physiology of nervous system and the mechanism and modulation of acute and chronic pain.~To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ET
Description: To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate.
Study: NCT00300768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg moxidectin
Description: Single-dose, tablet encapsulated for blinding

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivermectin 150 mcg/kg
Description: Single-dose, tablets encapsulated for blinding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg moxidectin
Description: Single dose, tablets encapsulated for blinding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 mg moxidectin
Description: single dose, tablets encapsulated for blinding
Study: NCT00797836

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quantiferon Gold
Description: Interferon-gama release assay evaluating tuberculosis-specific T-lymphocytic response~Health Personnel Hospitals, General Occupational Diseases/\*epidemiology/\*statistics \& numerical data Occupational Exposure/\*statistics \& numerical data~Tuberculosis/\*diagnosis/\*epidemiology/prevention \& control Immunologic Tests/methods/\*standards Disease Transmission, Horizontal/\*statistics \& numerical data Patient Isolation~Tuberculin Test/standards/\*methods Immunoassay/methods/\*standards T-Lymphocytes/immunology Interferon Type II/\*blood/\*analysis~\*Reagent Kits, Diagnostic~Mass Screening/\*methods Incidence Follow-Up Studies Comparative Study Sensitivity and Specificity Risk Assessment/\*methods
Study: NCT03447951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Para-Toluenesulfonamide
Description: A total dose of PTS100 in this study, the expected accumulated dose in the treatment duration, depends on the patient's tumour size. For each patient, up to 4 tumors, each not exceeding 8.8 cm in diameter, are selected for treatment by the joint decision of the investigator and the radiologist. The total dose is defined as the accumulated dose in treatment duration. The total dose is assigned as 30% of TTV for each patient and maximum TTV should be less than 366 cm3.
Study: NCT03659851

Intervention type: DRUG
Intervention: Levosimendan 2.5 MG/ML Injectable Solution
Description: LVAD implantation